The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial

The aim of the HYLAN M study was to investigate if symptoms and/or signs of patients suffering from severe dry eye disease (DED) can be improved by substituting individually optimized artificial tear therapy by high molecular weight hyaluronan (HMWHA) eye drops. In this international, multicenter st...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2020-11, Vol.9 (11), p.3536
Main Authors: van Setten, Gysbert-Botho, Baudouin, Christophe, Horwath-Winter, Jutta, Böhringer, Daniel, Stachs, Oliver, Toker, Ebru, Al-Zaaidi, Sultan, Benitez-del-Castillo, Jose M., Beck, Ria, Al-Sheikh, Osama, Seitz, Berthold, Barabino, Stefano, Reitsamer, Herbert A., Müller-Lierheim, Wolfgang G.K.
Format: Article
Language:English
Subjects:
Chronic fatigue syndrome
Cornea
Eye diseases
Hyaluronic acid
Inflammation
Lubricants & lubrication
Medicin och hälsovetenskap
Molecular weight
Pain
Pathophysiology
Patients
Quality of life
Questionnaires
Reading
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the HYLAN M study was to investigate if symptoms and/or signs of patients suffering from severe dry eye disease (DED) can be improved by substituting individually optimized artificial tear therapy by high molecular weight hyaluronan (HMWHA) eye drops. In this international, multicenter study, patients with symptoms of at least ocular surface disease index (OSDI) 33 and corneal fluorescein staining (CFS) of at least Oxford grade 3 were included. A total of 84 per-protocol patients were randomized in two study arms. The control group continued to use their individual optimum artificial tears over the study period of eight weeks; in the verum group, the artificial tears were substituted by eye drops containing 0.15% HMWHA. At the week 8 visit, the average OSDI of the verum group had improved by 13.5 as compared to the control group (p = 0.001). The best corrected visual acuity (BCVA) had improved by 0.04 logMAR (p = 0.033). CFS, tear film break-up time (TBUT), Schirmer I, lid wiper epitheliopathy (LWE), mucocutaneous junction (Yamaguchi score), and tear osmolarity were not significantly different between the verum and control groups (p > 0.050). We conclude that for most patients with severe DED, 0.15% HMWHA eye drops provide excellent improvement of symptoms without impairment of dry eye signs.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm9113536